Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Lilly, BMS Stop Enrollment in One of Two Phase III Lung Cancer Trials Due to Safety Concerns

By Pharmaceutical Processing | February 2, 2011

Eli Lilly and Company and Bristol-Myers Squibb Company  announced today that they have stopped
enrollment in one of their two global Phase III studies evaluating necitumumab,
an investigational anti-cancer agent, as a first-line treatment for advanced
non-small cell lung cancer (NSCLC).

The randomized, multi-center, open-label Phase III trial,
named INSPIRE, is evaluating the addition of necitumumab, a fully-human IgG1 monoclonal
antibody, to a combination of ALIMTA (pemetrexed for injection) and cisplatin
compared to a regimen of ALIMTA and cisplatin, as a first-line treatment for
patients with advanced nonsquamous NSCLC. No new safety issues were seen in the
control arm with Alimta and cisplatin.

The decision to stop enrollment followed an independent Data
Monitoring Committee (DMC) recommendation that no new or recently enrolled
patients continue treatment in the trial because of safety concerns related to
thromboembolism (blood clots) in the experimental arm of the study. The DMC
also noted that patients who have already received two or more cycles of
necitumumab appear to have a lower ongoing risk for these safety concerns.
These patients may choose to remain on the trial, after being informed of the
additional potential risks. Investigators will continue to assess patients
after two cycles to determine if there is a potential benefit from treatment.

As noted earlier, necitumumab continues to be studied in a
Phase III trial named SQUIRE. This study is evaluating necitumumab as a potential
treatment for a different type of lung cancer called squamous non-small cell
lung cancer in combination with GEMZAR (gemcitabine HCl for injection) and
cisplatin. The same independent DMC recommended that this trial continue
because no safety concerns have been observed.

“Patient safety is paramount. While stopping enrollment
in one of the two Phase III trials is disappointing, the SQUIRE Phase III study
of necitumumab in lung cancer continues,” said Richard Gaynor, M.D., vice president,
oncology product development and medical affairs for Lilly.

“Lilly remains committed to developing new medicines
that can help treat this devastating disease.” Lilly has contacted all
trial investigators to provide detailed information on how to manage
individuals enrolled in the trial, and has notified all pertinent regulatory
agencies of this decision.

Necitumumab is being developed in a partnership between
Lilly and Bristol-Myers Squibb. The two companies share development costs and any
potential commercialization within the U.S.,
Canada and Japan, while Lilly has exclusive
commercialization rights in all other countries.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE